Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.

@article{Kobashigawa2006TacrolimusWM,
  title={Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.},
  author={Jon Kobashigawa and Leslie W. Miller and Stuart D. Russell and Gregory A. Ewald and Mark Jay Zucker and Lee R. Goldberg and Howard J. Eisen and Kathryn Salm and D Tolzman and Jeff Gao and William E. Fitzsimmons and Roy First},
  journal={American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons},
  year={2006},
  volume={6 6},
  pages={1377-86}
}
The most advantageous combination of immunosuppressive agents for cardiac transplant recipients has not yet been established. Between November 2001 and June 2003, 343 de novo cardiac transplant recipients were randomized to receive steroids and either tacrolimus (TAC) + sirolimus (SRL), TAC + mycophenolate mofetil (MMF) or cyclosporine (CYA) + MMF. Antilymphocyte induction therapy was allowed for up to 5 days. The primary endpoint of >/=3A rejection or hemodynamic compromise rejection requiring… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 89 extracted citations

Similar Papers

Loading similar papers…